Search

everythinglearnresearchcommunity

for

Search:↓

PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The user is experiencing hair regrowth using daily 5% minoxidil and weekly microneedling, and plans to add finasteride soon. They are considering the effectiveness of once-daily minoxidil and adjusting microneedling needle size.

The user switched from topical minoxidil to oral minoxidil (2.5 mg) and finasteride (1 mg) after two years without results, noticing some initial shedding but no significant side effects. Others in the conversation discuss similar experiences with these treatments, including shedding, body hair growth, and varying results.

Oral minoxidil is considered more convenient and effective than topical or sublingual forms, with users reporting positive results and minimal side effects. Some users experience side effects with oral minoxidil and opt for sublingual or topical methods instead.

Oral minoxidil is considered more effective for hair regrowth than topical minoxidil, but it carries higher risks. Combining microneedling with topical minoxidil can enhance absorption, but oral minoxidil with microneedling shows significant results.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

OP plans to switch from topical to oral minoxidil due to limited results and is advised to overlap both for a few weeks before discontinuing the topical. Oral minoxidil may be more effective for non-responders to topical treatment.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.